Literature DB >> 10608029

Association Between Body Weight and In-Hospital Clinical Outcome Following Thrombolytic Therapy: A Report from the National Registry of Myocardial Infarction.

.   

Abstract

Background: In epidemiologic studies, excessive body weight, independent of other risk factors, portends a poor prognosis among patients with coronary artery disease experiencing acute myocardial infarction (MI). At least one recent study has suggested that patients of excessive body weight when receiving thrombolytic therapy are often under-dosed, potentially reducing early coronary arterial patency and adversely affecting in-hospital clinical outcome. Concern has also been raised that body weight may influence treatment utilization, delays, and complication rates. Despite these concerns, the association between body weight and patient outcome following coronary thrombolysis has received limited attention. Methods/
Results: Demographic, procedural, and outcome data from patients with MI were collected at 1073 United States hospitals participating in The National Registry of Myocardial Infarction from 1990 through 1994. Among 350,755 patients with MI enrolled, 87,688 (25.1%) were treated with tissue plasminogen activator (t-PA). Divided into body weight tertiles, 23.5% of patients were less than 70 kg (low weight), 36.8% were 70-85 kg (moderate weight), and 37.5% were greater than 85 kg (high weight). Patients of low weight were older (p < 0.001), received treatment later (p < 0.001), and were less likely to undergo cardiac catheterization, coronary angioplasty, or bypass surgery (p < 0.001) than moderate- or high-weight patients. Low-weight patients also experienced minor bleeding, major bleeding, recurrent MI, and death more often (p < 0.001). Adjusted for age, low body weight was independently associated with in-hospital mortality. Despite receiving a lower dose of t-PA per kg body weight, high-weight patients had a low incidence of cardiogenic shock, recurrent MI, death, and hemorrhagic complications.When high-weight women and men were compared, several interesting observations emerged. Mortality was increased twofold in women (6.8% vs. 3.0; p < 0.001), even adjusting for their older age. Despite being at increased risk, women were less likely than their male counterparts to undergo cardiac catheterization (p = 0.001) or bypass surgery (p = 0.008). Conclusions: The National Registry of Myocardial Infarction provides a unique resource for assessing health care trends in the United States. Our findings suggest that low body weight is associated with increased in-hospital morbidity and mortality. They also suggest that current dosing strategies for t-PA administration are probably adequate for high-weight patients. The excessive mortality and limited use of in-hospital interventions among high-weight women deserve further study to address gender-related differences in disease processes, as well as potential bias or discrimination.

Entities:  

Year:  1995        PMID: 10608029     DOI: 10.1007/bf01062715

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Relationship of relative weight and body mass index to 14-year mortality in the Chicago Peoples Gas Company study.

Authors:  A R Dyer; J Stamler; D M Berkson; H A Lindberg
Journal:  J Chronic Dis       Date:  1975-02

2.  Relationships between obesity and associated health factors with unemployment among low income women.

Authors:  D A Roe; K R Eickwort
Journal:  J Am Med Womens Assoc (1972)       Date:  1976-05

3.  Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens.

Authors:  R W Smalling; R Schumacher; D Morris; K Harder; F Fuentes; R P Valentine; L L Battey; M Merhige; D E Pitts; H A Lieberman
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

4.  Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators.

Authors:  L A Karagounis; J L Anderson; S G Sorensen; F L Moreno
Journal:  Am J Cardiol       Date:  1994-01-01       Impact factor: 2.778

5.  Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.

Authors:  P Tanswell; U Tebbe; K L Neuhaus; L Gläsle-Schwarz; J Wojcik; E Seifried
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

Review 6.  Tailored thrombolytic therapy. A perspective.

Authors:  M L Simoons; A E Arnold
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

7.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.

Authors:  W J Rogers; L J Bowlby; N C Chandra; W J French; J M Gore; C T Lambrew; R M Rubison; A J Tiefenbrunn; W D Weaver
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

8.  Sex bias in considering coronary bypass surgery.

Authors:  J N Tobin; S Wassertheil-Smoller; J P Wexler; R M Steingart; N Budner; L Lense; J Wachspress
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

9.  Obesity in relation to morbidity and mortality from cardiovascular disease.

Authors:  H Noppa; C Bengtsson; H Wedel; L Wilhelmsen
Journal:  Am J Epidemiol       Date:  1980-06       Impact factor: 4.897

10.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more
  1 in total

Review 1.  Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.

Authors:  Walter S Schroeder; Pritesh J Gandhi
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.